Altris IMS is an FDA-cleared (510(k)) ophthalmic data-management system. Intended for use by eye-care professionals in clinical workflows to manage patient imaging data and generate clinical reports & support research workflows by enabling:
Identification and visualization of OCT imaging features commonly associated with DR, including diffuse edema, subretinal fluid, vitelliform material, intraretinal hyperreflective foci, and microaneurysm-like signals, as well as less frequently described features such as epiretinal fibrosis and retinal surface irregularities.
Quantitative measurements of selected DR-related imaging features, with spatial information presented on ETDRS-style maps and B-scan visualizations.
FDA approved AI DR tools that allow users to review how image-derived features change over time in research settings.
For research use only. Not for diagnostic or clinical decision-making.
Platform overview
Only practical features for eye care specialists and clinical research
The security of patients’ data is our top priority: we are GDPR compliant, all data is encrypted, CE-certified, and FDA-cleared (510k) as an IMS system.
The system provides tools for research-focused review of longitudinal OCT data for USA retina studies to observe changes in image-derived features associated with diabetic retinopathy (DR). Automated comparisons of imaging data across multiple visits can be viewed through percentage-based displays, maps, and graphs. Thus, the Pathology Progression module offers quantitative, image-derived measurements of selected DR-related features, including fine-scale changes, to support research analysis.
- Automated identification and visualization of imaging features associated with DR to support efficient image-review workflows.
- Objective, quantitative measurements of DR-related imaging features for use in research.
- Visualization of feature changes over time, supported by maps and graphical displays.
- Longitudinal image-based data to assist with analysis and stratification activities in research settings.
For research use only. Not for diagnostic or clinical decision-making.
Label all the biomarkers of DR with color-coding
Explore DR biomarkers in terms of area, volume
How Altris works?
What makes Altris effective for Diabetic Retinopathy research?
Altris is a web-based platform developed by professionals with expertise in retinal imaging. The system is built using a large collection of OCT scans, thousands of which have been manually annotated for research and development purposes. These data support AI-based image-analysis tools that can:
For research use only. Not for diagnostic or clinical decision-making.
Formats
DICOM format will help you to extract maximum information. However, the system works with all
data formats, such as jpg, and png
OCT equipment
Altris is vendor-neutral. We work with the OCT data from 8 OCT manufacturers
OCT reports
We create comprehensible OCT reports for patients and eye care specialists based on historical research
For Pharma
For innovative approach in pharma
Contact usWhat you get:
- Centralized OCT Data Management
- Historical Data Analysis
- Vendor-neutral analysis of OCT scans (8 manufacturers)
- Data Security & Compliance
- Additional capabilities for research
- 40+retinal biomarkers studied in research across 30+ retinal conditions. For Research Use Only. Not for diagnostic procedures.
- Quantitative exploration of 40+biomarkers for Research Use Only. Not for diagnostic procedures.
- Reports
For Eye Care
IMS for Ophthalmology and Optometry
Contact usWhat you get:
- Centralized OCT Data Management
- Vendor-Neutral OCT Compatibility (8 manufacturers)
- Secure & Compliant Data Environment
- Historical OCT Data Analysis
- Seamless Clinical Workflow Integration
- 40+retinal biomarkers studied in research across 30+ retinal conditions. For Research Use Only. Not for diagnostic procedures.
- Quantitative exploration of 40+biomarkers for Research Use Only. Not for diagnostic procedures.